Regeneron faces Wall Street downgrades after high-profile melanoma drug fails to beat Mercks Keytruda
Regeneron Pharmaceuticals Inc (NASDAQ:REGN), the US biotech group, fell premarket trading on Monday after its most closely watched clinical trial of…